bpc-157 recovery 🧬 Peptide Therapy How BPC 157 and TB

BPC-157 is a synthetic peptide that may promote tissue repair and recovery by supporting cellular regeneration in muscles, tendons, ligaments, and organs

Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely

Factors to Consider When Choosing Between Stem Cell Therapy and PRP Newport Beach patients should consider several key factors when choosing between stem cell therapy and PRP therapy

Urban et al., 2025)

higher for those who stayed on treatment HbA1c fell by 1.91 percentage points from a mean baseline of 8.2% 73.5% of participants reached HbA1c 6.5%, a normal blood sugar threshold Compared to 15.9% with placebo Diabetes patients typically lose less weight on GLP-1 drugs than non-diabetic patients this pattern holds with CagriSema